Hospitals’ 340B savings for the first five of the 21 companies to impose conditions on 340B pricing when providers use contract pharmacies decreased by an estimated $1.1 billion from 2020 to 2021, hospital group 340B Health said in a new report today.
For the five manufacturers—AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, and Sanofi—savings fell by 49% for critical access hospitals and by 26% for all other 340B hospitals, the group said. Twenty-one manufacturers have such policies. “These five drugmakers represent only 22% of the total savings associated with restricted drugs, meaning the current impact for all 21 drugmakers is substantially higher,” 340B Health said.
Hospitals’ 340B savings for the first five of the 21 companies to impose conditions on 340B pricing when providers use contract pharmacies decreased by an estimated $1.1 billion from 2020 to 2021, hospital group 340B Health said in a new […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
